Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIPS-III metformin after STEMI
NL-OMON39113Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) and heart failure (HF) comparing Metformin with Placebo (2 arms). Primary endpoint: Left ventricular ejection fraction at 4 months. Started Jan 2011; status: active, not recruiting.
02
Drugs
metformin
03
Conditions
myocardial infarction (MI)heart failure (HF)
Beyond the preview
Go deeper on NL-OMON39113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39113.